10 Feb 2017 15:19
10 February 2017
Kromek Group plc
("Kromek" or the "Company")
Director/PDMR Shareholding
Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, announces that it has today received notification that Dr. Arnab Basu, Chief Executive Officer of the Company, today exercised options over 80,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), at an exercise price of 1.5 pence per Ordinary Share, pursuant to the EMI share option scheme.
Following the purchase, Dr. Basu has an interest in 2,952,000 Ordinary Shares representing 1.92% of the entire current issued share capital of the Company.
Enquiries
Kromek Group plc | |
Arnab Basu, CEO Derek Bulmer, CFO | +44 (0)1740 626 060 |
Cenkos Securities plc | |
Bobbie Hilliam (NOMAD) Julian Morse (Sales) | +44 (0)20 7397 8900 |
Luther Pendragon Ltd | |
Harry Chathli, Claire Norbury, Alexis Gore | +44 (0)20 7618 9100 |
About Kromek Group plc
Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.
The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.
The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").
The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.
Currently, the Group has over a hundred full time employees across its global operations. Further information on Kromek Group is available at www.kromek.com.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. The information set out below is provided in accordance with the requirements of Article 19(3) of that Regulation.
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Dr Arnab Basu | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Executive Officer | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Kromek Group plc | ||||
b)
| LEI
| N/a | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 1p each
| ||||
b)
| Nature of the transaction
| Exercise of options over Ordinary Shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
|
80,000
1.5p (exercise price)
| ||||
e)
| Date of the transaction
| 10 February 2017 | ||||
f)
| Place of the transaction
| N/a | ||||
Kromek (KMK)